Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals;Tratamiento de infecciones por Enterococcus resistente a vancomicina con linezolid en un hospital pediátrico

Farmacia Hospitalaria

Volumn 31, Issue 1, 2007, Pages 43-47

  Travaglianti, Mónica ^a   Perez M ^a   Sberna, N ^a   Rousseau, M ^a   Calle, G ^a   Gomez S ^a  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Adverse drug reaction reporting; Linezolid; Risk factors; Serious paediatric infections; Vancomycin resistant Enterococcus

Indexed keywords

LINEZOLID; VANCOMYCIN;

ARTICLE; CHILD; CLINICAL ARTICLE; DEATH; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROCOCCAL INFECTION; FEMALE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; MALE; PEDIATRIC HOSPITAL;

EID: 34247397806     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(07)75710-0     Document Type: Article

References (18)

1. DeLisle S, Perl T. Vancomycin-resistant Enterococci. A road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest 2003; 123 (Supl. 5): 504S-18S.
2. Mera JR, Arduino RC, Correa AP, Coque TM, Stamboulian D, Murray BE. First report of vancomycin-resistant Enterococcus faecium isolated in Argentina. Clin Infect Dis 1998; 26: 235-6.
3. Paladino J. Linezolid: An oxazolidinone antimicrobial agent. Am J Health Syst Pharm 2002; 59: 2413-25.
4. DRUGDEX® System. Thomson Micromedex, Greenwood Village, Colorado (Edition expires 2005).
5. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford M, et al. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin Infect Dis 1995; 20: 1126-33.
6. Malik RK, Montecalvo MA, Reale MR, Li K, Maw M, Muñoz JL, et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J 1999; 18: 352-6.
7. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factor for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20: 318-23.
8. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993-1000.
9. Sanderson R. Vancomycin-resistant enterococci (VRE) [monografía en internet]. Bureau of Epidemiology: Florida Department of Health; 2000 (consultado 29-07-2005). Available at: http://www.doh.state. fl.us/Disease_ctrl/epi/htopics/reports/vre.pdf
10. Pérez M, Sberna N. Linezolid [monografía en internet]. Boletín CIME, Fundación Hospital de Pediatría Juan P. Garrahan. 2004, No 34 (citado 31-07-2005). Disponible en: http://www.garrahan. gov.ar/cime/boletines/ linezolid.pdf
11. Calle G, Rousseau M, Hermilla MV, Lemos N. Evaluación y prevención de reacciones adversas. Farmacovigilancia: experiencia en el Hospital Garrahan. Medicina Infantil. Revista del Hospital de Pediatría Garrahan 2004; 11: 94-100.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
13. Uppsala Monitoring Centre (UMC). Vigilancia de la seguridad de los medicamentos. Guía para la instalación y puesta en funcionamiento de un centro de Farmacovigilancia [monografía en internet]. UMC-WHO. 2001 (consultado 30-07-05). Disponible en: http://www.who-umc.org/graphics/4808.pdf
14. Winterstein AG, Hatton RC, González-Rothi R, Johns TE, Segal R. Significant clinically preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health-Syst Pharm 2002; 59: 1742-9.
15. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, González-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: A literature review. Am J Health Syst Pharm 2003; 60: 1750-9.
16. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
17. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al, en representación del Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-86.
18. Buck M. Linezolid use for resistant gram-positive infections in children [monografía en internet]. Pediatr Pharm 2003; 9 (consultado 30-07-05). Disponible en: http://www.healthsystem.virginia.edu/internet/pediatrics/pharma- news/June2003.pdf